CEO Blog: Why biOasis Matters

2015 saw a major turning point for us – an event that occurred on the results of the MedImmune Neuropathic Pain Program. This program not only further validated our Transcendpep as compared to Transcend, it also showed that the pep version was far better than the full-length Transcend. The advantages of pep vs. the full-length are many and from an asset perspective, it truly increases our technical valuation significantly.

Since this discovery, the attractiveness of biOasis in the market has risen significantly. What we have shown the marketplace is that our technology belongs here and it has a strong opportunity to succeed. Consequently, the doors have opened for active discussions between biOasis and interested parties and we currently has over 30 companies talking to us about how our technology could be used within their organizations.

A natural question to arise from all of this is why does biOasis matter right now? There’s a clear answer – originality, acceptance, and economics.

For years, the neurological challenge of how to defeat the blood-brain barrier overlooked natural processes as possible solutions. What biOasis has developed is a means to get therapeutic compounds across the blood-brain barrier by working with it, rather than against it. This natural process initiated by us has been accepted as not only a novel idea that no one else is doing, but also the correct one. Lastly, the economics of using a peptide vs. the full-length sequence has made our technology more desirable and appealing than the more costly alternative.

At biOasis, we aren’t shy about our technology and our results. As such, we have invited companies to collaborate with us, test our technology internally, and see for themselves what the potential is for what we have worked so carefully to develop. For our company, this increases the possibility of commercial agreements and reinforcing biOasis as a clear industry front-runner that matters. Right now.

Rob Hutchison is the CEO of biOasis Technologies Inc, a biopharmaceutical company focused on the delivery of therapeutics across the Blood-Brain Barrier and into the brain tissue with its proprietary Transcend Platform.

By biOasis Technologies Inc.|Wednesday, December 16, 2015|CEO Blog